EPHB6 and neoplasm: Taken together, our observations suggest an intriguing model, whereby EPHB6 accelerates expansion of TNBC TICs, while also increasing tumour sensitivity to DNA-damaging compounds and potentially other therapies selectively affecting proliferating cells, probably by driving TICs out of their slow-proliferating, resistant state.